Hanmi Science

Beta

KRX Filings & Disclosures 2026

Risk Factors

• • Hanmi Science group 10% KRW/USD move → ±KRW 1.64B pre-tax earnings impact, up from ±KRW 0.61B prior year
• • Hanmi Pharm 10% KRW/USD move → ±KRW 15.65B pre-tax earnings impact, up from ±KRW 13.36B prior year

Management Discussion & Analysis

• • Revenue KRW 1.357T (+5.7% YoY), operating profit KRW 138.7B (+40.3%), net income KRW 117.7B (+107.6%)
• • Healthcare segment revenue KRW 155.1B (+19.8%), operating profit KRW 23.1B (+21.2%) driven by medical device and consumer health product sales increase

Business Overview

• • Business model: holding company with revenue from equity method income, patent/trademark royalties, healthcare products, and pharmaceutical wholesale totaling KRW 1.36T in FY2025
• • November 2022 acquisition and integration of Hanmi Healthcare added medical devices, food manufacturing/distribution, beauty care, and pharma IT solutions segments

What are the latest Hanmi Science DART filings in 2026?

Hanmi Science (KRX code 008930) has filed an annual report on March 20, 2026 with DART. SignalX tracks every new DART disclosure with AI-powered English summaries of business overview, risk factors, and management discussion.

When did Hanmi Science file its most recent annual report?

Hanmi Science filed its most recent annual report on March 20, 2026. The annual report includes audited financial statements, business overview, risk factors, and management discussion (MD&A), all available on SignalX with AI-generated English summaries and KIFRS financial data.

What is Hanmi Science's KRX stock code?

Hanmi Science's KRX stock code is 008930. The 6-digit stock code is the KRX standard identifier for every listed security. You can use stock code 008930 to look up all Hanmi Science disclosures on DART, or browse them here on SignalX with AI-powered English analysis.

How often does Hanmi Science file with DART?

Korean listed companies file an annual report once per year (typically within 90 days of fiscal year-end), a half-year report once mid-year, and quarterly reports for Q1 and Q3 — three regular periodic disclosures plus the annual. Material event reports are filed as needed when corporate events occur. SignalX monitors DART daily.

What is the difference between annual, half-year, and quarterly reports in Korea?

An annual report is a comprehensive filing with audited financials, business overview, and risk factors — analogous to the US 10-K. A half-year (interim) report covers H1 results. Quarterly reports cover Q1 or Q3 — analogous to the US 10-Q but Korea publishes only two quarterly reports per year (with the half-year report covering Q2). SignalX provides AI-generated English summaries for all three filing types for Hanmi Science.

Where can I find Hanmi Science financial data and KIFRS metrics?

SignalX extracts KIFRS consolidated financial data from Hanmi Science annual reports, including revenue, gross profit, operating income, net income, total assets, stockholders' equity, EPS (basic/diluted), operating cash flow, and capital expenditure — all in KRW. Multi-year financial trends are displayed in the Financial Summary table above.